Document Detail


Prevalence of Helicobacter pylori infection in coronary artery disease and effect of its eradication on coronary lumen reduction after percutaneous coronary angioplasty.
MedLine Citation:
PMID:  11407666     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Gastric infection caused by Helicobacter pylori has recently been associated with increased risk of coronary artery disease. AIM: To: 1) determine seroprevalence of Helicobacter pylori and its cytotoxin associated gene A in patients with/without coronary artery disease (group A), 2) assess influence of Helicobacter pylori eradication on coronary artery lumen reduction after percutaneous coronary angioplasty (group B) and 3) determine influence of Helicobacter pylori eradication on plasma cytokines, lipids and coagulation factors in patients subjected to percutaneous coronary angioplasty (group B). PATIENTS AND METHODS: Group A included 100 patients with coronary artery disease (subgroup 1) and 100 patients without (subgroup II). For Helicobacter pylori seroprevalence, plasma anti-Helicobacter pylori and anti-cytotoxin associated gene A IgG were examined. Group B included 40 patients with significant single-vessel coronary arterial disease and Helicobacter pylori infection confirmed by 13C-urea breath test and serologically using anti-Helicobacter pylori and anti-cytotoxin associated gene A IgG. Six months after percutaneous coronary angioplasty and triple anti-Helicobacter pylori therapy, the Helicobacter pylori status reassessed by urea breath test was negative in all but two patients of subgroup I subjected to Helicobacter pylori therapy. Coronary angiography and laboratory tests were repeated in both subgroups of group B included in the trial and reduction in coronary artery lumen in these subgroups was compared to baseline after percutaneous coronary angioplasty considered as 100%. RESULTS: Helicobacter pylori seropositivity reached 81.5% of coronary artery disease (subgroup I) and was significantly higher than that in controls without coronary artery disease (subgroup II) (51%), the odds ratio being 4.3 for Helicobacter pylori in coronary artery disease. Cytotoxin associated gene A IgG detection was also significantly higher (47.3%) in coronary artery disease than in controls (28%) giving the odds ratio about 2.3. Mean coronary artery lumen reduction in patients undergoing percutaneous coronary angioplasty + Helicobacter pylori eradication therapy (subgroup I) was significantly (p<0.05) smaller compared to percutaneous coronary angioplasty + placebo-treated subgroup II (22% vs 41%). CONCLUSIONS: 1) There is a significant link between coronary artery disease and infection with Helicobacter pylori, especially expressing CagA proteins, 2) Helicobacter pylori eradication significantly attenuates reduction in coronary artery lumen in coronary artery disease patients after percutaneous coronary angioplasty possibly by elimination of chronic inflammation and decline in proinflammatory cytokine release, and 3) Infection of Chlamydia pneumoniae in these percutaneous coronary angioplasty patients is not affected by eradication therapy.
Authors:
M Kowalski; P C Konturek; P Pieniazek; E Karczewska; A Kluczka; R Grove; W Kranig; R Nasseri; J Thale; E G Hahn; S J Konturek
Related Documents :
9283726 - Anatomic variant of the posterior interventricular coronary artery: implications for co...
2524296 - Emergency coronary bypass not associated with preoperative cardiogenic shock in failed ...
2295746 - Myocardial salvage after failed coronary angioplasty.
6778166 - Percutaneous transluminal angioplasty: general principles.
9203596 - Primary coronary artery bypass grafting without cardiopulmonary bypass in impaired left...
21860706 - Apical hypertrophic cardiomyopathy.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver     Volume:  33     ISSN:  1590-8658     ISO Abbreviation:  Dig Liver Dis     Publication Date:  2001 Apr 
Date Detail:
Created Date:  2001-06-15     Completed Date:  2001-11-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100958385     Medline TA:  Dig Liver Dis     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  222-9     Citation Subset:  IM    
Affiliation:
Hertzcentrum Osnabruck-Bad Rothenfelde, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Age Distribution
Aged
Angioplasty, Transluminal, Percutaneous Coronary / methods*
Case-Control Studies
Comorbidity
Coronary Disease / diagnosis,  epidemiology*,  therapy*
Female
Follow-Up Studies
Helicobacter Infections / diagnosis*,  epidemiology*
Helicobacter pylori / isolation & purification*
Humans
Male
Middle Aged
Poland / epidemiology
Prevalence
Recurrence
Reference Values
Sensitivity and Specificity
Severity of Illness Index
Sex Distribution
Treatment Outcome
Comments/Corrections
Comment In:
Dig Liver Dis. 2001 Apr;33(3):214-6   [PMID:  11407664 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study S...
Next Document:  Efficacy and safety of Nd:YAG laser for the treatment of bleeding from radiation proctocolitis.